Judd Moul, MD,FACS

Dr. Judd W. Moul is James H. Semans, MD Professor of Surgery, Division of Urologic Surgery, and Director of the Duke Prostate Center, Duke Cancer Institute at Duke University Medical Center. Prior to joining Duke, he was Professor of Surgery at the Uniformed Services University of the Health Sciences (USUHS) in Bethesda, Maryland and an attending Urologic Oncologist at the Walter Reed Army Medical Center (WRAMC) in Washington, DC. In 2004, he completed a 26-year U.S. Army career, retiring as a full Colonel in the Medical Corps, and became Chief of the Division of Urologic Surgery at Duke.
Dr Moul currently serves on the editorial boards of Prostate Cancer and Prostatic Diseases, BJU International, American Journal of Men’s Health, Urology, World Journal of Urology, and Oncology. He has published over 625 medical and scientific manuscripts and book chapters and has lectured at national and international meetings as a prostate cancer authority. Honors and awards received have included the American Medical Association’s Young Physicians Section Community Service Award for his national involvement in prostate cancer patient support groups, the Sir Henry Welcome Research Medal and Prize from the Association of Military Surgeons of the United States, and the prestigious Gold Cystoscope Award by the American Urological Association.
Financial relationships
-
Attribution:SelfType of financial relationship:Meeting Participant or Lecturer (Oncology)Ineligible company:Sanofi-AventisMitigation strategy:Peer reviewDate reviewed:09/20/2022
-
Attribution:SelfType of financial relationship:Meeting Participant or Lecturer (Oncology)Ineligible company:DendreonMitigation strategy:Peer reviewDate reviewed:09/20/2022
-
Attribution:SelfType of financial relationship:Consultant or Advisor (Oncology)Ineligible company:BayerMitigation strategy:Peer reviewDate reviewed:09/20/2022
-
Attribution:SelfType of financial relationship:Meeting Participant or Lecturer (Oncology)Ineligible company:Blue Earth DiagnosticsMitigation strategy:Peer reviewDate reviewed:09/20/2022
-
Attribution:SelfType of financial relationship:Meeting Participant or Lecturer (Oncology)Ineligible company:Genomic HealthMitigation strategy:DivestDate reviewed:09/20/2022
-
Attribution:SelfType of financial relationship:Meeting Participant or Lecturer (Oncology)Ineligible company:FerringMitigation strategy:DivestDate reviewed:09/20/2022
-
Attribution:SelfType of financial relationship:Meeting Participant or Lecturer (Oncology)Ineligible company:Exosome DxMitigation strategy:Peer reviewDate reviewed:09/20/2022
-
Attribution:SelfType of financial relationship:Consultant or Advisor (Oncology)Ineligible company:TolmarMitigation strategy:Peer reviewDate reviewed:09/20/2022
-
Attribution:SelfType of financial relationship:Meeting Participant or Lecturer (Oncology)Ineligible company:AstellasMitigation strategy:Peer reviewDate reviewed:09/20/2022
-
Attribution:SelfType of financial relationship:Scientific Study or Trial (Oncology)Ineligible company:PfizerMitigation strategy:Peer reviewDate reviewed:09/20/2022